Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
暂无分享,去创建一个
M. Cazzola | P. Vyas | G. Mufti | K. Götze | P. Greenberg | M. Voso | E. Vellenga | B. Quesnel | A. Verma | G. Garcia-Manero | P. Fenaux | E. Hellström-Lindberg | T. Cluzeau | L. Adès | C. Finelli | M. Sekeres | U. Germing | D. Bowen | U. Platzbecker | V. Santini | A. Zeidan | O. Beyne-Rauzy | R. Buckstein | A. List | J. Jurcic | M. Sherman | R. Komrokji | A. Rampersad | O. Ilhan | M. Savona | D. Selleslag | B. Arrizabalaga | A. DeZern | M. Díez-Campelo | F. Salvi | A. Laadem | D. Mazure | J. Falantes | V. Giai | Jennie Zhang | A. Benzohra | Diana R Dunshee | P. Linde | D. Dunshee
[1] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[2] A. Raza,et al. Rewriting the rules for care of MDS and AML patients in the time of COVID-19 , 2020, Leukemia Research Reports.
[3] A. Verma,et al. Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes. , 2020, The Journal of clinical investigation.
[4] C. Camaschella. GDF11 is not the target of luspatercept. , 2019, Blood.
[5] S. Rivella,et al. Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of beta-thalassemia. , 2019, Blood.
[6] G. Garcia-Manero,et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. , 2019, Blood.
[7] G. Garcia-Manero,et al. The role of TGFβ in hematopoiesis and myeloid disorders , 2019, Leukemia.
[8] P. Fenaux,et al. Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis. , 2019, Blood.
[9] P. Valent,et al. Anemia at older age: etiologies, clinical implications, and management. , 2018, Blood.
[10] K. Götze,et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study. , 2017, The Lancet. Oncology.
[11] A. List,et al. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond. , 2017, Seminars in hematology.
[12] A. Stamatoullas,et al. Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] G. Mufti,et al. Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Stamatoullas,et al. A randomized phase II trial of azacitidine +/− epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents , 2016, Haematologica.
[15] Mario Cazzola,et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.
[16] A. Stamatoullas,et al. Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion , 2016, Leukemia.
[17] K. Usuki. [Treatment of MDS]. , 2014, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[18] S. Rivella,et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. , 2014, Blood.
[19] A. Grinberg,et al. Transforming growth factor-β superfamily ligand trap ACE-536 corrects anemia by promoting late-stage erythropoiesis , 2014, Nature Medicine.
[20] L. Möllgård,et al. Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial , 2014, Blood Cancer Journal.
[21] J. Melo,et al. Transfusion Dependency Is Associated With Inferior Survival Even In Very Low and Low Risk IPSS-R Patients , 2013 .
[22] M. Cazzola,et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. , 2013, Blood.
[23] A. Stamatoullas,et al. Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS? , 2013, Blood.
[24] A. Stamatoullas,et al. Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents , 2013, Leukemia.
[25] Luca Malcovati,et al. Revised international prognostic scoring system for myelodysplastic syndromes. , 2012, Blood.
[26] A. Hutchings,et al. A review of anemia as a cardiovascular risk factor in patients with myelodysplastic syndromes. , 2011, American journal of blood research.
[27] L. Malcovati. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes. , 2009, Clinical lymphoma & myeloma.
[28] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[29] M. Bitzer,et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.
[30] H. Dombret,et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. , 2008, Blood.
[31] M. Cazzola,et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[33] M. Cazzola,et al. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. , 2006, Haematologica.
[34] Luca Malcovati,et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Cazzola,et al. Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. , 2005, Blood.
[36] B. Zhivotovsky,et al. Granulocyte colony-stimulating factor inhibits spontaneous cytochrome c release and mitochondria-dependent apoptosis of myelodysplastic syndrome hematopoietic progenitors. , 2003, Blood.
[37] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[38] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[39] E. Hellström-Lindberg. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta‐analysis of 205 patients from 17 studies , 1995, British journal of haematology.